A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer as first line treatment (REVIVAL study)

Trial Profile

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer as first line treatment (REVIVAL study)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Olaparib (Primary) ; Capecitabine; Carboplatin
  • Indications Advanced breast cancer; Male breast cancer; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REVIVAL study
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
    • 20 Jan 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top